PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
June 1, 2005Cardiovascular Research

Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does intracoronary delivery of adenovirus containing the PLADP gene improve cardiac function in 12-14-week-old BIO 14.6 cardiomyopathic hamsters?

Population

12-14-week-old BIO 14.6 cardiomyopathic hamsters

Comparison

Intracoronary delivery of adenovirus containing… vs Intracoronary delivery of adenovirus containing…

Design

Preclinical

Follow-up

4-5 days

Authors

TDThomas DieterleMMMarkus MeyerYGYingying Gu

Discussion

Loading...

Member takes

Overview

Extends preclinical gene therapy evidence in cardiomyopathy models; leaves open human translation and safety.

Structured PICO

Does intracoronary delivery of adenovirus containing the PLADP gene improve cardiac function in 12-14-week-old BIO 14.6 cardiomyopathic hamsters?

P
Population
12-14-week-old BIO 14.6 cardiomyopathic hamsters
I
Intervention
Intracoronary delivery of adenovirus containing the PLADP (phospholamban-targeted antibody) gene (8 x 10(9) PFU per animal)
C
Comparator
Intracoronary delivery of adenovirus containing the beta-galactosidase (LacZ) gene or saline (Sham)
O
Outcome
Echocardiographic and hemodynamic indices of left ventricular function at 4-5 days after gene transfersurrogate

In vivo adenoviral gene transfer of a phospholamban-targeted antibody improves LV function and intracellular calcium handling in a hamster model of heart failure.

Cite This Study

Dieterle et al. (2005) studied this question.

synapsesocial.com/papers/6a1beef41567d2fc4d5f47b9https://doi.org/10.1016/j.cardiores.2005.04.029
View Full Paper
Ask AI
Bookmark
Share